Efficacy Assessment of the Cell Therapy Medicine NC1 in Patients With Post-traumatic Syringomyelia (CME-LEM4)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02807142 |
Recruitment Status :
Completed
First Posted : June 21, 2016
Last Update Posted : April 5, 2018
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Post-Traumatic Syringomyelia | Biological: NC 1 cell therapy | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 6 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Efficacy Assessment of the Cell Therapy Medicine NC1 in Patients With Post-traumatic Syringomyelia |
Study Start Date : | March 2016 |
Actual Primary Completion Date : | February 7, 2018 |
Actual Study Completion Date : | February 7, 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: NC 1 cell therapy
All patients will be treated with the same treatment: NC1 cell therapy
|
Biological: NC 1 cell therapy
All patients will be treated with NC1 |
- Efficacy of the treatment with NC1 in terms of improvement of neurological sequelae in patients with post traumatic syringomyelia using the ASIA scale (American Spinal Injury Association [ Time Frame: Pretreatment, month 3 post treatment, month 6 post treatment ]Neurological evaluation is done using ASIA scale (American Spinal Injury Association)
- Safety, by the assessment of the adverse events of the study [ Time Frame: 1 year ]Adverse events
- Efficacy of the treatment with NC1 in terms of improvement of neurological sequelae in patients with post traumatic syringomyelia assessed with the IANR-SCIFRS scale (Injury Functional Rating Scale) [ Time Frame: Pretreatment, month 3 post treatment, month 6 post treatment ]Neurological evaluation is done using IANR-SCIFRS scale (Injury Functional Rating Scale)
- Efficacy of the treatment with NC1 in terms of improvement of neurological sequelae in patients with post traumatic syringomyelia in terms of spams frequency [ Time Frame: Pretreatment, month 3 post treatment, month 6 post treatment ]Neurological evaluation is done using PENN scale (spams frequency score)
- Efficacy of the treatment with NC1 in terms of improvement of neurological sequelae in patients with post traumatic syringomyelia in term of spasticity [ Time Frame: Pretreatment, month 3 post treatment, month 6 post treatment ]Neurological evaluation is done using Ashworth scale (spasticity)
- Efficacy of the treatment with NC1 in terms of improvement of neurological sequelae in patients with post traumatic syringomyelia using the Visual Analog Scale [ Time Frame: Pretreatment, month 3 post treatment, month 6 post treatment ]Neurological evaluation is done using EVA scale (Visual Analog Scale)
- Efficacy of the treatment with NC1 in terms of improvement of neurological sequelae in patients with post traumatic syringomyelia in terms of bladder functionality [ Time Frame: Pretreatment, month 3 post treatment, month 6 post treatment ]Neurological evaluation is done using GEFFNER scale (bladder functionality)
- Efficacy of the treatment with NC1 in terms of improvement of neurological sequelae in patients with post traumatic syringomyelia using the Behavior Dimensions Scale [ Time Frame: Pretreatment, month 3 post treatment, month 6 post treatment ]Neurological evaluation is done using BDS scales (Behavior Dimensions Scale)
- Efficacy of the treatment with NC1 in terms of improvement of neurological sequelae in patients with post traumatic syringomyelia in terms of somatosensory or motor evoked potentials [ Time Frame: Pretreatment, month 3 post treatment, month 6 post treatment ]Present of somatosensory or motor evoked potentials
- Efficacy of the treatment with NC1 in terms of improvement of neurological sequelae in patients with post traumatic syringomyelia by electromyography [ Time Frame: Pretreatment, month 3 post treatment, month 6 post treatment ]EMG (Electromyography)
- Efficacy of the treatment with NC1 in terms of improvement of neurological sequelae in patients with post traumatic syringomyelia studying the spinal cord morphology [ Time Frame: Pretreatment, month 3 post treatment, month 6 post treatment ]Spinal cord morphology (by Magnetic Resonance)
- Efficacy of the treatment with NC1 in terms of improvement of neurological sequelae in patients with post traumatic syringomyelia in terms of defecatory function [ Time Frame: Pretreatment, month 3 post treatment, month 6 post treatment ]Neurological evaluation is done assessing the defecatory function

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with traumatic medullar injury (levels A, B, C or D of the ASIA scale) and associated syringomyelia in at least three spinal segments, and with neurological deficit clinically stable at least 6 months prior to treatment.
- Previous studies in Neurophysiology, MR, Urology (if data on neurogenic bowel exists), defecatory function (if data on neurogenic intestine exists)
- Age between 18 and 70 years old.
- Presence of syringomyelia based on a neuro-image (MR)
- Patients will compromise to use anticonceptive measures from the cell extraction until 6 months after the administration of the treatment.
- Patients will compromise to a clinical follow-up and to perform physical therapy, one hour daily five days per week during the treatment period.
- Patients should sign an written informed consent.
- Haematological and creatinin parameters, SGOT and SGPT into the normal ranges.
Exclusion Criteria:
- Patients under 18 or above 70 years old
- Pregnancy or breastfeeding
- Neoplasia in the last 5 years
- Patients with systemic diseases that increase the risk of the surgical intervention
- Genetics alterations that could conduct to cellular transformation during the cellular expansion phase.
- Patients not really sure of their cooperation to follow the physical therapy or clinical controls during the study.
- Additional neurodegenerative diseases
- Drug consuming, psychiatric disease or allergy to proteins used during cellular expansion
- HIV or syphilis positive serologies
- Active Hepatitis B or c, based on serologies
- Any other reasons according to the investigator criteria.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02807142
Principal Investigator: | Jesús Vaquero Crespo, M.D. | Hospital Universitario Puerta de Hierro-Majadahonda |
Responsible Party: | Jesús Vaquero Crespo, M.D., M.D., Puerta de Hierro University Hospital |
ClinicalTrials.gov Identifier: | NCT02807142 |
Other Study ID Numbers: |
CME-LEM4 |
First Posted: | June 21, 2016 Key Record Dates |
Last Update Posted: | April 5, 2018 |
Last Verified: | April 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Anonymized individual data of participants will be shared with Authorities at the end of the Clinical Development Plan by the CTD (Common Technical Document). Results will be published in a scientific publication. |
Time Frame: | Starting at CTD submission to authorities. |
Access Criteria: | Spanish competent authority. |
Syringomyelia Spinal Cord Diseases Central Nervous System Diseases Nervous System Diseases |